Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study.
He says the contract is projected to deliver £3.5mln in revenue all of which is expected to be recognised in 2020.